Any current/future new fundraising through debt or equity?

The company has reduced overall borrowings by approximately INR 450 crores in the current year. Working capital management has improved, with tighter controls on receivables and inventory. Despite higher crude prices, the company expects to require only around INR 100 crores of incremental working capital. Cash generation from higher volumes and better margins is expected to comfortably cover growth investments, shareholder payouts, and incremental working capital needs. There is no explicit mention of new fundraising through debt or equity in the provided transcript. The management emphasizes

Any current/future capex/capital investment/strategic investment?

PCBL Chemical Limited is in the process of expanding capacity for green chelates in Aquapharm, awaiting product approvals from P&G, Henkel, and others before setting up additional capacity. The company plans significant capacity additions for Aquapharm's green chelates portfolio in FY27 and FY28 as sales increase. A pilot plant for the battery chemicals business (Nanovace) at Palej is ready for commissioning soon, with commercial volumes expected to start in FY28 after validation. A project on coal-tar-based feedstock diversification is underway, with feasibility being finalized and capex inve

Future growth expectations in sales/revenue/volumes?

Carbon black volume growth expected at high single digits (7-10%) for FY27 with more than double-digit EBITDA growth. Green chelates (Aquapharm) revenue expected to grow significantly, with 20-25% top-line growth forecast for FY27. Expansion plans underway for green chelates capacity post product approvals from P&G and Henkel; trial orders received and supplies started. Tyre business volumes expected to increase from Q1 FY27 onwards, recovering from slight QoQ decline. Aquapharm EBITDA projected to improve strongly, targeting INR75 crores quarterly run rate, and potentially INR50-55 crores EBI

Future growth expectations in earnings/operating earnings/profits/EPS?

PCBL Chemical Limited expects **double-digit growth in EBITDA per ton for FY27**, with a 14-15% increase anticipated due to pricing, product mix improvements, and cost initiatives. **Volume growth** for carbon black is expected to be **high single digits (7-10%)** next year, driving overall revenue and profitability growth. The Aquapharm segment is projected to see **20-25% top-line growth in FY27**, with EBITDA expected to increase significantly, potentially returning to INR50-55 crores per quarter. The company anticipates **higher tyre business volumes from Q1 FY27 onwards**. Profita

Current/ Expected Orderbook/ Pending Orders?

PCBL Chemical has started receiving trial orders from key customers like P&G and Henkel for their green chelates portfolio (Aquapharm segment). Supplies for these trial orders have commenced, with significant volume and revenue ramp-up expected from Q2 and Q3 FY27 onwards as product approvals come through. The potential market opportunity for these customers is large, exceeding their current capacity of 4,000 tons, indicating plans for capacity expansion once approvals are received. The company is also working with additional customers for product approvals in the non-detergent segment to broa

IN US

Sale is live|00:00:00left today

PCBL Chemical LtdQ1 FY26Chemicals & Petrochemicals

PCBL Chemical Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹317P/E: 50.3Market Cap: ₹10.8K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Carbon black volume growth expected at high single digits (7-10%) for FY27 with more than double-digit EBITDA growth.
→Green chelates (Aquapharm) revenue expected to grow significantly, with 20-25% top-line growth forecast for FY27.
→Expansion plans underway for green chelates capacity post product approvals from P&G and Henkel; trial orders received and supplies started.
→Tyre business volumes expected to increase from Q1 FY27 onwards, recovering from slight QoQ decline.
→Aquapharm EBITDA projected to improve strongly, targeting INR75 crores quarterly run rate, and potentially INR50-55 crores EBITDA per quarter next year.
→Market expansions through India-EU FTA and increased exports to the US post tariff reduction expected to drive volume and revenue growth.
→Battery chemical segment (Nanovace) to begin commercial volume ramp-up from FY28 after pilot plant commissioning and product validations.
→Overall revenue growth driven by volume increases, improved product mix, pricing, and cost efficiency initiatives.

Margin guidance

Category 1

→PCBL Chemical Limited expects **double-digit growth in EBITDA per ton for FY27**, with a 14-15% increase anticipated due to pricing, product mix improvements, and cost initiatives.
→**Volume growth** for carbon black is expected to be **high single digits (7-10%)** next year, driving overall revenue and profitability growth.
→The Aquapharm segment is projected to see **20-25% top-line growth in FY27**, with EBITDA expected to increase significantly, potentially returning to INR50-55 crores per quarter.
→The company anticipates **higher tyre business volumes from Q1 FY27 onwards**.
→Profitability is expected to **surpass FY25 base case EBITDA and PAT** levels.
→Long-term guidance remains robust, with a target of INR40 billion EBITDA by 2030 still on track despite current short-term challenges.
→Battery chemicals business pilot is ready; **commercial volumes expected from FY28**, contributing future profits.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has reduced overall borrowings by approximately INR 450 crores in the current year.
→Working capital management has improved, with tighter controls on receivables and inventory.
→Despite higher crude prices, the company expects to require only around INR 100 crores of incremental working capital.
→Cash generation from higher volumes and better margins is expected to comfortably cover growth investments, shareholder payouts, and incremental working capital needs.
→There is no explicit mention of new fundraising through debt or equity in the provided transcript.
→The management emphasizes maintaining capital discipline and generating cash internally to fund growth and reduce leverage.

Order book

→PCBL Chemical has started receiving trial orders from key customers like P&G and Henkel for their green chelates portfolio (Aquapharm segment).
→Supplies for these trial orders have commenced, with significant volume and revenue ramp-up expected from Q2 and Q3 FY27 onwards as product approvals come through.
→The potential market opportunity for these customers is large, exceeding their current capacity of 4,000 tons, indicating plans for capacity expansion once approvals are received.
→The company is also working with additional customers for product approvals in the non-detergent segment to broaden the order book.
→Overall, the order pipeline is strong, with Aquapharm expected to see 20-25% revenue growth in FY27 fueled by these new and incremental allocations.

Capex plans

Yes

→PCBL Chemical Limited is in the process of expanding capacity for green chelates in Aquapharm, awaiting product approvals from P&G, Henkel, and others before setting up additional capacity.
→The company plans significant capacity additions for Aquapharm's green chelates portfolio in FY27 and FY28 as sales increase.
→A pilot plant for the battery chemicals business (Nanovace) at Palej is ready for commissioning soon, with commercial volumes expected to start in FY28 after validation.
→A project on coal-tar-based feedstock diversification is underway, with feasibility being finalized and capex investment sign-off expected in upcoming calls.
→Cost reduction initiatives targeting INR 200-250 crores savings over 4-6 quarters are ongoing, including yield improvement, throughput enhancement, and feedstock diversification.
→PCBL aims to continue investing in growth capex while reducing overall debt, with net leverage expected to decline.

How does PCBL Chemical Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1PCBL Chemical Ltd

Rev 2Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like PCBL Chemical Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio